Nabil Ismaili, Director of Medical Oncology and Radiotherapy Department at Mohammed VI University of Sciences and Health, shared on LinkedIn:
“T-1 before ESMO 2026 in Madrid!
I am incredibly honored to be representing UM6SS, Cheikh Khalifa International University Hospital, and Mohammed VI International University Hospital at this global milestone in oncology.
Here is my selection based on the upcoming abstracts and LBAs
Lung Cancer
- DeLLphi-305 (LBA3): Tarlatamab + durvalumab in ES-SCLC. Can next-gen immunotherapy improve survival in extensive-stage disease?
- SAFFRON (LBA6): Osimertinib + savolitinib in MET-altered EGFR+ NSCLC. Can MET inhibition overcome resistance to osimertinib?
- Krasciendo 1 (LBA5): Divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC. Will a next-generation inhibitor improve outcomes?
- OptiTROP-Lung04 (LBA67): Sacituzumab tirumotecan (ADC) after EGFR-TKI progression. Does this ADC improve overall survival?
- SigVie-002 (LBA68): Sigvotatug vedotin vs docetaxel in previously treated nonsquamous NSCLC.
Breast Cancer
- NATALEE (6-Year Outcomes): Long-term outcomes of adjuvant ribociclib in HR+/HER2- early breast cancer. Crucial data to confirm durable long-term benefit.
- DESTINY-Breast09: CNS outcomes update with T-DXd + pertuzumab in HER2+ metastatic breast cancer.
- KEYNOTE-B49: Pembrolizumab + chemotherapy in PD-L1+ HR+/HER2- MBC. Can we expand the IO benefit to this population?
- TROPION-Breast02: CNS outcomes with datopotamab deruxtecan in Triple-Negative Breast Cancer (TNBC).
- FOURLIGHT-1: Atirmociclib (a novel CDK4 inhibitor) + fulvestrant in 2L HR+/HER2- MBC.
Gastrointestinal (GI) Cancer
- CLARITY-Gastric 01 (LBA7): Sonesitatug vedotin vs investigator’s choice in CLDN18.2+ gastric/GEJ cancer. Validating the ADC approach in this target.
- HARMONI-GI1 (LBA8): Ivonescimab (PD-1/VEGF) + chemo vs durvalumab + chemo in 1L advanced biliary tract cancer.
- MATTERHORN-02 (LBA9): Perioperative FOLFIRINOX ± IO in resectable pancreatic cancer. Refining the perioperative standard in high-risk disease.
- DESTINY-Gastric04 (LBA10): T-DXd in earlier lines for HER2+ gastric/GEJ cancer. Moving T-DXd earlier to improve survival.
- COMPANION-002 (4590): Tovecimab (DLL4/VEGF bispecific) + paclitaxel in 2L+ biliary tract cancer.
Genitourinary (GU) Cancer
- DASL-HiCaP (LBA4): Darolutamide + ADT + definitive/salvage RT in localized, very high-risk prostate cancer. A new standard for intensification?
- VOLGA (LBA2): Perioperative durvalumab + tremelimumab + neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer.
- LITESPARK-012 (35860): 1st-line pembrolizumab + lenvatinib + belzutifan in advanced RCC.
- CAPItello-281 (LBA56): Capivasertib + abiraterone vs placebo + abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer.
- PROTEUS (LBA53): Perioperative apalutamide + ADT around radical prostatectomy in high-risk localized prostate cancer.”
You can also read: 20 Posts Not to Miss from ESMO Congress 2026: Day 1
